Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Trial Profile

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Brimapitide (Primary)
  • Indications Sensorineural hearing loss
  • Focus Registrational; Therapeutic Use
  • Acronyms ASSENT
  • Sponsors Auris Medical
  • Most Recent Events

    • 24 Feb 2017 According to an Auris Medical media release, the company expects to announce top-line results from this trial in the second half of 2018.
    • 18 Aug 2016 According to Auris Medical media release, top-line results are expected in the first half of 2018.
    • 17 Jun 2016 Status changed from planning to recruiting, as reported in an Auris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top